BGPT: Paper Review: Epigenetic modifications as regulatory elements of autophagy in cancer

Explore by Goal

Quick Explanation Copied

Concise critique — Sui et al., 2015 (Cancer Letters)

This focused mini-review synthesizes evidence that DNA methylation, histone post‑translational modifications and epigenetically regulated miRNAs modulate autophagy in cancer — proposing epigenetic markers and epigenetic drugs (DNMT/HDAC modulators) as candidate ways to manipulate autophagy for diagnosis or therapy (review cites 112 refs)

Long Explanation

Visual paper review — "Epigenetic modifications as regulatory elements of autophagy in cancer" (Sui et al., 2015)

Visual-first summary of claims, evidence strength, blindspots, and concrete next experiments. Visualizations below are derived from the paper's structure and reference counts.

Key takeaways (visual first)

Supported links: DNA hypermethylation of tumor suppressors and autophagy genes (e.g., Beclin1, LC3A, ATG5) is repeatedly reported and correlates with reduced autophagic gene expression in tumors cited by the review
Mechanistic depth: The paper collates mechanistic work showing histone acetylation/deacetylation and methylation modulate Atg protein acetylation and chromatin at autophagy gene promoters (e.g., EP300, KAT5/TIP60, G9a) — plausible direct links to autophagy induction
Translational claims: Sui et al. propose diagnostic/prognostic uses (methylation markers) and therapeutic modulation (HDAC inhibitors, DNMT inhibitors) to alter autophagy and chemosensitivity; evidence for clinical benefit in patients, however, is thin in 2015 and mostly preclinical (caveat below)

Critical appraisal — strengths and limitations

Strengths:

Comprehensive scope in 2014–2015: synthesizes DNA methylation, histone PTMs and miRNA control with specific autophagy genes and epigenetic enzymes (useful cross-disciplinary summary).
Useful tables (1 and 2) mapping genes/enzymes to autophagy outcomes — a practical quick reference.
Translational framing (biomarkers, DNMT/HDAC drugs) aligns with ongoing epigenetic therapy research and spurs testable hypotheses.

Limitations and blindspots:

Evidence mix: most cited functional claims derive from cell lines and some animal studies; clinical correlative data are limited in 2015, so causal clinical translation remains speculative
Context dependence: autophagy is tumor-suppressive in early tumorigenesis but tumor-promoting in established tumors — the review notes this duality but cannot resolve when epigenetic-induced autophagy will be beneficial vs harmful in therapy.
Selective citation risk: as a narrative mini-review it may reflect positive-result bias and lacks systematic search/meta-analysis; negative or contradictory findings are less visible (publication bias risk).
Reproducibility info lacking: being a review, it does not present original methods/data nor preregistered synthesis approach; reproducibility depends on the underlying primary studies (variable quality).

Where the claims would be falsified

Large, independent cohorts showing no association between promoter methylation of proposed autophagy genes (e.g., Beclin1, LC3A) and their transcript/protein expression would falsify the proposed widespread regulatory role.
Perturbation experiments in orthotopic patient-derived xenografts or organoids where reversing methylation/HDAC activity fails to alter autophagy metrics or treatment response would challenge direct therapeutic utility.

Concrete, testable next experiments (visual + short)

Experiment A — Clinical correlative panel

Measure promoter methylation (bisulfite sequencing) and mRNA/protein of Beclin1, LC3A, ATG5 in 200 paired tumor/normal samples across 3 tumor types; correlate with autophagy flux (LC3-II accumulation ± bafilomycin) and treatment outcome. This will quantify clinical effect sizes and confounders.

Experiment B — Organoid functional test

Use patient-derived organoids with known methylation of LC3A/Beclin1; apply DNMTi (decitabine) ± HDACi (vorinostat) and measure autophagy flux, viability, and chemo-sensitivity to standard drugs; include controls reversing methylation via targeted CRISPR-dCas9-TET.

Evidence-weighted recommendations

Use methylation of autophagy genes as exploratory biomarkers in prospective trials, not yet for clinical decision-making.
Design combination therapy trials that prospectively measure autophagy endpoints (flux assays, LC3-II, p62) when testing epigenetic drugs + cytotoxics/targeted agents.
Prioritize organoid/PDX validation across tumor subtypes before broad translation because epigenetic–autophagy relationships are context dependent.

Paper metrics (from provided metadata)

Publication date: May 01, 2015; References: 112
Declared conflicts: none; Funding: Chinese national/regional grants

Quick verdict

A useful, well-referenced mini-review that maps epigenetic regulators onto autophagy biology and translational hypotheses; limits are typical for narrative reviews — preclinical-heavy evidence and limited clinical validation to 2015.

Selected citations used to support critique (detailed extracts)

- The review itself — primary object of critique:

- Autophagy machinery context and checkpoints:

- Clinical/translational caution about epigenetic therapies:

Author-level followups

Run bespoke Author Reviews for the paper's authors:

Final concise guidance:

Treat Sui et al. (2015) as a valuable, well-indexed map of epigenetic–autophagy literature up to 2014 that should be followed by focused clinical correlative studies and organoid/PDX functional validation before translational application.

Feedback:

Updated: February 24, 2026